NEW DELHI: The nasal vaccine from Bharat Biotech, which was licenced for use in India's COVID-19 immunization programme last week, would cost Rs 800 in addition to GST of 5%, according to government sources. By the end of January, private vaccination clinics would offer the intra-nasal vaccine.
The vaccine has previously been licenced for use as a primary vaccine for a complete two-dose course against COVID-19 as well as a booster shot for patients who have already received Covaxin or Covishield.
A senior government official told Moneycontrol that "Bharat Biotech had approached us for price fixation of its intranasal and it has now been approved; the vaccine is likely to be available in less than a month in private hospitals."
Amid a recent spike in COVID cases, PM Modi urges everyone to get vaccinated. In light of the growing COVID dangers, Prime Minister Narendra Modi has warned his countrymen and advised everyone to get properly immunised, especially those who fall into the susceptible category.
The government has encouraged those who qualify to take the precautionary dose and behave in a manner consistent with Covid, such as by donning masks and keeping a social distance.
According to sources, This time, the BF.7 version of the Covid-19 virus is reportedly more contagious and has a shorter incubation period. In China, the new variety is already causing havoc with thousands of new Covid cases being reported daily. There has been a sharp increase in Covid-19 instances in other nations as well, including Argentina, South Korea, Japan, and the US. The Indian government has also issued severe preventive steps and encouraged individuals to take all vaccinations, including the booster dose, in light of the virus's widespread distribution over the world.
In order to assess readiness for any potential increase in Covid-19 infections, mock exercises are being staged on Tuesday in numerous locations throughout India. The Union government, state governments, and union territory governments have all stepped up during the Covid-19 outbreak in China and internationally, issuing guidelines to monitor the cost and availability of necessary medications as well as the availability of oxygen.
Also watch: